Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2020

Aug 13, 2020

SELL
$0.41 - $0.73 $31,857 - $56,722
-77,702 Closed
0 $0
Q1 2020

May 14, 2020

SELL
$0.36 - $0.79 $1,665 - $3,654
-4,626 Reduced 5.62%
77,702 $32,000
Q4 2019

Feb 14, 2020

BUY
$0.75 - $0.89 $15,258 - $18,106
20,344 Added 32.82%
82,328 $63,000
Q3 2019

Nov 14, 2019

SELL
$0.78 - $1.09 $77,629 - $108,482
-99,525 Reduced 61.62%
61,984 $55,000
Q2 2019

Aug 14, 2019

SELL
$0.98 - $1.64 $93,642 - $156,708
-95,554 Reduced 37.17%
161,509 $185,000
Q1 2019

May 15, 2019

SELL
$0.67 - $1.01 $4,060 - $6,121
-6,061 Reduced 2.3%
257,063 $250,000
Q4 2018

Feb 14, 2019

SELL
$0.63 - $1.0 $118,755 - $188,501
-188,501 Reduced 41.74%
263,124 $185,000
Q3 2018

Dec 21, 2021

BUY
$0.88 - $1.1 $45,915 - $57,394
52,177 Added 13.06%
451,625 $450,000
Q3 2018

Nov 14, 2018

BUY
$0.88 - $1.1 $18,657 - $23,322
21,202 Added 5.61%
399,448 $397,000
Q2 2018

Apr 21, 2020

BUY
$0.91 - $1.45 $57,897 - $92,254
63,624 Added 20.22%
378,246 $367,000
Q2 2018

Aug 14, 2018

SELL
$0.91 - $1.45 $1.15 Million - $1.83 Million
-1,263,731 Reduced 80.07%
314,622 $304,000
Q1 2018

Oct 18, 2019

SELL
$0.84 - $1.18 $42 - $60
-51 Reduced -0.0%
1,578,353 $1.72 Million
Q1 2018

May 15, 2018

BUY
$0.84 - $1.18 $177,600 - $249,486
211,429 Added 15.47%
1,578,404 $1.72 Million
Q4 2017

Feb 14, 2018

BUY
$0.68 - $1.0 $929,508 - $1.37 Million
1,366,924 Added 2680243.25%
1,366,975 $1.17 Million
Q3 2017

Nov 14, 2017

BUY
$0.39 - $0.66 $19 - $33
51
51 $0

Others Institutions Holding PTN

# of Institutions
1
Shares Held
2.94K
Call Options Held
0
Put Options Held
0

About PALATIN TECHNOLOGIES INC


  • Ticker PTN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 9,290,480
  • Market Cap $10.5M
  • Description
  • Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing o...
More about PTN
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.